Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,424.85 162.29 1.00%
S&P 500 1,862.31 19.33 1.05%
NASDAQ 4,086.22 52.06 1.29%
Ticker Volume Price Price Delta
STOXX 50 3,139.26 47.74 1.54%
FTSE 100 6,584.17 42.56 0.65%
DAX 9,317.82 144.11 1.57%
Ticker Volume Price Price Delta
NIKKEI 14,417.68 420.87 3.01%
TOPIX 1,166.55 30.46 2.68%
HANG SENG 22,696.01 24.75 0.11%

Rigel Announces Participation at Two Investor Conferences



          Rigel Announces Participation at Two Investor Conferences

PR Newswire

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2013

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2013 /PRNewswire/ -- Rigel
Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower,
chairman and chief executive officer, and Ryan Maynard, executive vice
president and chief financial officer of Rigel, will participate at two
upcoming investor conferences. Details of the events are as follows:

Cowen and Company 33^rd Annual Health Care Conference 
Date: Wednesday, March 6 at 8:40 a.m. ET 
Location: Boston, MA 
Speaker: Ryan Maynard

25^th Annual ROTH Conference 
Date: Monday, March 18 at 4:00 p.m. PT 
Location: Laguna Niguel, CA 
Speaker: James M. Gower

Both events will be webcast live and can be accessed at www.rigel.com.  Please
connect to Rigel's website several minutes prior to the start of the live
webcast to ensure adequate time for any software download that may be
necessary.

About Rigel (www.rigel.com) 
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a clinical-stage drug
development company that discovers and develops novel, small-molecule drugs
for the treatment of inflammatory and autoimmune diseases, as well as muscle
disorders. Rigel's pioneering research focuses on intracellular signaling
pathways and related targets that are critical to disease mechanisms. Rigel's
productivity has resulted in strategic collaborations with large
pharmaceutical partners to develop and market its product candidates. Current
product development programs include fostamatinib, an oral SYK inhibitor that
is in Phase 3 clinical trials for rheumatoid arthritis with its partner
AstraZeneca; R343, an inhaled SYK inhibitor for asthma and R333, a topical
JAK/SYK inhibitor for discoid lupus – both of which have commenced Phase 2
clinical trials; and, R348, a topical JAK/SYK inhibitor in a Phase 1 clinical
trial for the treatment of chronic dry eye.

Contact: Ryan Maynard 
Phone: 650.624.1284 
Email: invrel@rigel.com

 

SOURCE Rigel Pharmaceuticals, Inc.

Website: http://www.rigel.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement